참고문헌 (29)

1. Antonia, S. J., Borghaei, H., Ramalingam, S. S., Horn, L., De Castro？Carpeno, J., Pluzanski, A., Burgio, M. A., Garassino, M., Chow, L.？Q. M., Gettinger, S., Crino, L., Planchard, D., Butts, C., Drilon, A.,？Wojcik-Tomaszewska, J., Otterson, G. A., Agrawal, S., Li, A., Penrod, J. R. and Brahmer, J. (2019) Four-year survival with nivolumab？in patients with previously treated advanced non-small-cell lung？cancer: a pooled analysis. Lancet Oncol. 20, 1395-1408. 

   상세보기

2. Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P.？L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J.？B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Shipp,？M. A., Kato, K., Sumbul, A., Farsaci, B. and Ansell, S. M. (2018)？Nivolumab for relapsed/refractory classic Hodgkin lymphoma after？failure of autologous hematopoietic cell transplantation: extended？follow-up of the multicohort single-arm phase II CheckMate 205？trial. J. Clin. Oncol. 36, 1428-1439. 

   상세보기

3. Bernard-Tessier, A., Baldini, C., Martin, P., Champiat, S., Hollebecque,？A., Postel-Vinay, S., Varga, A., Bahleda, R., Gazzah, A., Michot,？J. M., Ribrag, V., Armand, J. P., Marabelle, A., Soria, J. C. and？Massard, C. (2018) Outcomes of long-term responders to antiprogrammed death 1 and anti-programmed death ligand 1 when？being rechallenged with the same anti-programmed death 1 and？anti-programmed death ligand 1 at progression. Eur. J. Cancer？101, 160-164. 

4. Budagian, V., Bulanova, E., Paus, R. and Bulfone-Paus, S. (2006) IL15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 17, 259-280. 

5. Cheng, L. E., Ohlen, C., Nelson, B. H. and Greenberg, P. D. (2002)？Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and？expansion of responding CD8+ T cells rather than promotion of cell？death. Proc. Natl. Acad. Sci. U. S. A. 99, 3001-3006. 

6. Dranoff, G. (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11-22. 

   상세보기

7. Floros, T. and Tarhini, A. A. (2015) Anticancer cytokines: biology and？clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21,？and IL-12. Semin. Oncol. 42, 539-548. 

8. Fradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang,？N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A.,？Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C.？N., Nam, K., Frenkl, T. L., Perini, R. F., de Wit, R. and Bajorin,？D. F. (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent？advanced urothelial cancer: results of >2 years of follow-up. Ann.？Oncol. 30, 970-976. 

9. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R.？and Louie, A. C. (1995) Results of treatment of 255 patients with？metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696. 

   상세보기

10. Goldstein, D. and Laszlo, J. (1988) The role of interferon in cancer？therapy: a current perspective. CA Cancer J. Clin. 38, 258-277. 

11. Isaacs, A. and Lindenmann, J. (1988) Classics in oncology: virus interference: I. the interferon. CA Cancer J. Clin. 38, 280-290. 

12. Jauch, D., Martin, M., Schiechl, G., Kesselring, R., Schlitt, H. J.,？Geissler, E. K. and Fichtner-Feigl, S. (2011) Interleukin 21 controls？tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut 60, 1678-1686. 

    상세보기

13. Jenks, S. (1996) After initial setback, IL-12 regaining popularity. J.？Natl. Cancer Inst. 88, 576-577. 

    상세보기

14. Katze, M. G., He, Y. and Gale, M., Jr. (2002) Viruses and interferon: a？fight for supremacy. Nat. Rev. Immunol. 2, 675-687. 

    상세보기

15. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan,？S., Loudon, R., Sherman, F., Perussia, B. and Trinchieri, G. (1989)？Identification and purification of natural killer cell stimulatory factor？(NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-845. 

    상세보기

16. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P.,？Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer,？R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Marquez-Rodas,？I., Haanen, J., Guidoboni, M., Maio, M., Schoffski, P., Carlino, M.？S., Lebbe, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G.？V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S. and？Wolchok, J. D. (2019) Five-year survival with combined nivolumab？and ipilimumab in advanced melanoma. N. Engl. J. Med. 381,？1535-1546. 

    상세보기

17. MaruYama, T., Chen, W. and Shibata, H. (2022) TGF-beta and cancer？immunotherapy. Biol. Pharm. Bull. 45, 155-161. 

18. Mishra, A., Sullivan, L. and Caligiuri, M. A. (2014) Molecular pathways:？interleukin-15 signaling in health and in cancer. Clin. Cancer Res.？20, 2044-2050. 

    상세보기

19. Ruscetti, F. W. (1984) Biology of interleukin-2. Surv. Immunol. Res.？3, 122-126. 

    상세보기

20. Saenz, S. A., Taylor, B. C. and Artis, D. (2008) Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol. Rev. 226, 172-190. 

    상세보기

21. Saka, H., Nishio, M., Hida, T., Nakagawa, K., Sakai, H., Nogami, N.,？Atagi, S., Takahashi, T., Horinouchi, H., Takenoyama, M., Katakami,？N., Tanaka, H., Takeda, K., Satouchi, M., Isobe, H., Maemondo, M.,？Goto, K., Hirashima, T., Minato, K., Yada, N. and Tamura, T. (2021)？Five-year follow-up results from phase II studies of nivolumab in？Japanese patients with previously treated advanced non-small cell？lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies. Jpn. J. Clin. Oncol. 51, 106-113. 

22. Sim, G. C. and Radvanyi, L. (2014) The IL-2 cytokine family in cancer？immunotherapy. Cytokine Growth Factor Rev. 25, 377-390. 

23. Skrombolas, D. and Frelinger, J. G. (2014) Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor？therapy. Expert Rev. Clin. Immunol. 10, 207-217. 

24. Sondergaard, H. and Skak, K. (2009) IL-21: roles in immunopathology？and cancer therapy. Tissue Antigens 74, 467-479. 

    상세보기

25. Spolski, R. and Leonard, W. J. (2008) Interleukin-21: basic biology and？implications for cancer and autoimmunity. Annu. Rev. Immunol. 26,？57-79. 

    상세보기

26. Stolfi, C., Rizzo, A., Franze, E., Rotondi, A., Fantini, M. C., Sarra, M.,？Caruso, R., Monteleone, I., Sileri, P., Franceschilli, L., Caprioli,？F., Ferrero, S., MacDonald, T. T., Pallone, F. and Monteleone, G.？(2011) Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J. Exp. Med. 208, 2279-2290. 

    상세보기

27. Waldmann, T. A. (2004) Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res.？Ther. 6, 174-177. 

    상세보기

28. Waldmann, T. A. (2018) Cytokines in cancer immunotherapy. Cold？Spring Harb. Perspect. Biol. 10, a028472. 

    상세보기

29. Wang, X., Lupardus, P., Laporte, S. L. and Garcia, K. C. (2009) Structural biology of shared cytokine receptors. Annu. Rev. Immunol.？27, 29-60. 

    상세보기